文献速递眼底病与葡萄膜炎

美国印第安人或阿拉斯加原住民与非原住民美国人糖尿病视网膜病变患病率:系统综述与Meta分析

The Prevalence of Diabetic Retinopathy in American Indians or Alaska Natives and Non-Indigenous Americans: A Systematic Review and Meta-Analysis.
PubMed 文献 · Ophthalmology · 2025-08-13

本系统综述与Meta分析纳入53项研究共10,070,617名糖尿病患者,比较美国印第安人或阿拉斯加原住民(AIAN)与非AIAN患者的糖尿病视网膜病变(DR)患病率。AIAN组DR汇总患病率为21%(95%CI 13%-30%;GRADE低),非AIAN组为20%(95%CI 16%-25%;GRADE低),比较分析显示两组DR发生率可能无差异(OR 0.67;95%CI 0.31-1.48;GRADE低)。

要点

  • AIAN组DR汇总患病率21%(95%CI 13%-30%),非AIAN组20%(95%CI 16%-25%),证据质量均为低。
  • 两组DR发生率比较无差异(OR 0.67;95%CI 0.31-1.48;GRADE低)。
  • 两组DME患病率均为3%,但AIAN组PDR为3%、VTDR为3%,非AIAN组PDR为2%、VTDR为5%。

核心结论

  • AIAN与非AIAN糖尿病患者之间DR患病率似乎无显著差异,但证据受研究异质性限制。
  • 高疾病负担提示AIAN与非AIAN患者同样需要公共卫生策略。

研究设计与样本

  • 系统综述与Meta分析,检索Ovid MEDLINE、EMBASE和Web of Science数据库自建库至2025年2月23日。
  • 纳入评估美国糖尿病患者DR患病率的原始研究,共53项研究、10,070,617名个体。
  • 采用Freeman-Tukey双重反正弦变换和随机效应模型进行Meta分析,使用Joanna Briggs Institute患病率研究评估清单评估偏倚风险,采用GRADE评估证据确定性。

主要发现

  • AIAN组DR汇总患病率为21%(95%CI 13%-30%;GRADE低),非AIAN组为20%(95%CI 16%-25%;GRADE低)。
  • AIAN组PDR患病率为3%(95%CI 1%-6%;GRADE低),非AIAN组为2%(95%CI 1%-4%;GRADE低)。
  • AIAN组DME患病率为3%(95%CI 2%-4%;GRADE低),非AIAN组为3%(95%CI 2%-4%;GRADE低)。
  • AIAN组VTDR患病率为3%(95%CI 1%-7%;GRADE低),非AIAN组为5%(95%CI 4%-7%;GRADE低)。
  • 比较分析显示AIAN与非AIAN患者DR发生率可能无差异(OR 0.67;95%CI 0.31-1.48;GRADE低),缺乏高质量证据。

关键数值与推荐

  • DR患病率:AIAN组21%(95%CI 13%-30%;GRADE低)vs 非AIAN组20%(95%CI 16%-25%;GRADE低)。
  • PDR患病率:AIAN组3%(95%CI 1%-6%;GRADE低)vs 非AIAN组2%(95%CI 1%-4%;GRADE低)。
  • DME患病率:AIAN组3%(95%CI 2%-4%;GRADE低)vs 非AIAN组3%(95%CI 2%-4%;GRADE低)。
  • VTDR患病率:AIAN组3%(95%CI 1%-7%;GRADE低)vs 非AIAN组5%(95%CI 4%-7%;GRADE低)。
  • DR发生率比较:OR 0.67(95%CI 0.31-1.48;GRADE低)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据受研究异质性限制。
  • 缺乏高质量证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: To estimate the prevalence of diabetic retinopathy (DR) in adult American Indian or Alaska Native (AIAN) and non-AIAN patients with diabetes. CLINICAL RELEVANCE: Although diabetes mellitus is more prevalent among AIAN patients compared with non-AIAN patients, the evidence is inconsistent regarding whether AIAN patients have a higher prevalence or severity of DR. METHODS: We searched Ovid MEDLINE, EMBASE, and Web of Science databases from inception through February 23, 2025. We included primary studies evaluating the prevalence of DR in Americans with diabetes. The prevalence of (1) DR, (2) diabetic macular edema (DME), (3) proliferative diabetic retinopathy (PDR), (4) vision-threatening DR (VTDR; including DME, PDR, and severe nonproliferative DR), and (5) PDR complications were estimated. Meta-analyses were performed using Freeman-Tukey double arcsine transformations and random-effects modelling. The Joanna Briggs Institute Appraisal Checklist for Prevalence Studies was used to assess risk of bias. Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) guidelines were used to assess certainty of evidence. RESULTS: Overall, 53 studies of 10 070 617 individuals were included. In the AIAN and non-AIAN groups, the pooled prevalence of DR was estimated to be 21% (95% confidence interval [CI], 13%-30%; GRADE, low) and 20% (95% CI, 16%-25%; GRADE, low), respectively. The prevalence of PDR was estimated to be 3% (95% CI, 1%-6%; GRADE, low) and 2% (95% CI, 1%-4%; GRADE, low), respectively. The prevalence of DME was estimated to be 3% (95% CI, 2%-4%; GRADE, low) and 3% (95% CI, 2%-4%; GRADE, low), respectively. The prevalence of VTDR was estimated to be 3% (95% CI, 1%-7%; GRADE, low) and 5% (95% CI, 4%-7%; GRADE, low), respectively. High-quality evidence was lacking. Comparative analysis demonstrated that no difference may exist in the rate of DR between AIAN and non-AIAN patients (odds ratio, 0.67; 95% CI, 0.31-1.48; GRADE, low). DISCUSSION: No appreciable difference seems to exist in the prevalence of DR between AIAN and non-AIAN patients, although evidence is limited by the heterogeneity of studies. The high disease burden highlights that public health strategies are needed equally for AIAN as well as non-AIAN patients. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Yu CW, Nanji K, Garg A, et al. The Prevalence of Diabetic Retinopathy in American Indians or Alaska Natives and Non-Indigenous Americans: A Systematic Review and Meta-Analysis. Ophthalmology. 2025. PMID: 40816608. doi:10.1016/j.ophtha.2025.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。